← Back to Search

Cannabinoid

Effects of CBD on 2 Mile Run Time Trial Performance

N/A
Waitlist Available
Research Sponsored by University of Northern Colorado
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 10-25 minutes

Summary

This trial aims to investigate if CBD can help reduce anxiety and gut distress in female athletes, potentially improving their running performance.

Who is the study for?
This trial is for moderately active individuals who identify as female and are interested in how CBD might affect their two-mile run performance. Participants should be healthy with no major medical issues.
What is being tested?
The study is testing the effects of CBD capsules on running performance, specifically looking at anxiety levels, gut distress during endurance activities, and overall two-mile run times.
What are the potential side effects?
Potential side effects of CBD may include mild drowsiness, dry mouth, lightheadedness, and low blood pressure. Some people might also experience changes in mood or appetite.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~10-25 minutes
This trial's timeline: 3 weeks for screening, Varies for treatment, and 10-25 minutes for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Difference in Anxiety Measured with the State Trait Anxiety Inventory
Difference in Blood Lactate Concentrations
Difference in Gastrointestinal Distress
+2 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: CannabidiolExperimental Treatment1 Intervention
Cannabidiol capsules 2 hours prior to 2 mile run.
Group II: PlaceboPlacebo Group1 Intervention
Placebo capsules 2 hours prior to 2 mile run.

Find a Location

Who is running the clinical trial?

University of Northern ColoradoLead Sponsor
6 Previous Clinical Trials
487 Total Patients Enrolled
~14 spots leftby Dec 2025